ProCE Banner Activity

Studies From CROI 2022: PrEP Implementation and Treatment Access for HCV and TB in Eastern Europe

Clinical Thought
The data presented at CROI 2022 had particular relevance for the Central and Eastern European regions, where there are significant delays in PrEP for HIV, varied approaches to HIV/HCV coinfection, and a high prevalence of TB.

Released: March 11, 2022

Expiration: March 10, 2023

No longer available for credit.

Share

Faculty

Milosz Parczewski

Milosz Parczewski, MD, PhD

Professor of Medicine
Consultant Physician, ID Specialist
Head
Department of Infectious, Tropical Diseases and Immune Deficiency
Pomeranian Medical University
Szczecin, Poland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Cepheid

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Milosz Parczewski, MD, PhD

Professor of Medicine
Consultant Physician, ID Specialist
Head
Department of Infectious, Tropical Diseases and Immune Deficiency
Pomeranian Medical University
Szczecin, Poland

Milosz Parczewski, MD, PhD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, MSD, and ViiV/GlaxoSmithKline and fees for non-CME services from Gilead Sciences, Janssen, and MSD.